Abstract:Non-nucleoside reverse transcriptase inhibitors (NNRTIs) form the backbone of antiretroviral treatment for many HIV-infected individuals. The unique antiviral activity, high specificity and low toxicity associated with this class of agents make them a frequent choice for first-line therapy. However, the effectiveness of NNRTI drugs can be hampered by the rapid emergence of drug-resistant viruses, poor pharmacokinetic (PK) properties and severe side effects in long-term usage. Therefore, there is an urgent need to develop novel NNRTIs without such limitations. An analysis of this vast group of already existing inhibitors should constitute the basis of the effort toward the development of more potent, promising drugs or candidates.The present review provides an overview of NNRTI research from 2005 to 2010, and highlights some important medicinal chemistry principles and strategies in the development of NNRTIs.An in-depth analysis of the common binding configuration and structural features of NNRTIs, as well as the underlying clues to the 'follow-on'-based chemical evolution efforts (including the key medicinal chemistry principles and strategies: bioisosteric replacement, molecular hybridization, scaffold hopping, prodrug, etc.) has greatly accelerated the optimization of the pharmacodynamic (PD) and PK profiles. There is still a good deal of opportunity to discover new highly potent NNRTIs or novel scaffolds with unconventional mechanisms for reverse transcriptase (RT) inhibition.

Tyrosyl-tRNA synthetase inhibitors: a patent review

Thiopeptide Antibiotics Exhibit a Dual Mode of Action Against Intracellular Pathogens by Affecting Both Host and Microbe.

Aminoacyl-tRNA synthetase inhibitors as potent antibacterials.

Research Advances of Aminoacyl-tRNA Synthetase Inhibitors As Novel Anti-infective Agents

Synthesis and Evaluation of New Tyrosyl-Trna Synthetase Inhibitors As Antibacterial Agents Based on a N2-(arylacetyl)glycinanilide Scaffold

Recent Development of Leucyl-Trna Synthetase Inhibitors As Antimicrobial Agents.

Metronidazole Containing Pyrazole Derivatives Potently Inhibit Tyrosyl-Trna Synthetase: Design, Synthesis, and Biological Evaluation

Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).

In Silico Discovery of Aminoacyl-tRNA Synthetase Inhibitors

New molecular insights into the tyrosyl-tRNA synthase inhibitors: CoMFA, CoMSIA analyses and molecular docking studies.

Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: a Patent Review (2005 – 2010)

RNA-based Therapeutics: an Overview and Prospectus

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

[New Inhibitors Targeting Bacterial RNA Polymerase].

Mycobacterium tuberculosis inhibitors: an updated patent review (2021-present)

Ribosome-Targeting Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug Design

Enoyl Acyl Carrier Protein Reductase Inhibitors: A Patent Review (2006-2010)

Evolutionary Limitation and Opportunities for Developing Trna Synthetase Inhibitors with 5-Binding-mode Classification.

Adenosine Analogs As Inhibitors of Tyrosyl-Trna Synthetase: Design, Synthesis and Antibacterial Evaluation.

Ribosome‐targeting Antibacterial Agents: Advances, Challenges, and Opportunities

Ribosome-targeting antibacterial agents: Advances, challenges, and opportunities